While the introduction of novel therapies has led to substantial improvements in the outcomes of patients with newly ...

The first sign of multiple myeloma varies by person and may not occur until a later stage of the disease. Learn how to ...

So high-risk multiple myeloma, for example, include patients who have a deletion 17p or chromosome 1p deletion along with chromosome 1, you know, gain or amplification.

Preliminary clinical experience with anti-GPRC5D CAR T-cell therapy also has shown high response rates in relapsed/refractory myeloma that progressed after anti-BCMA CAR T-cell therapy.

ORLANDO — A high-fiber, plant-based dietary intervention and nutritional counseling improved several risk factors for multiple myeloma, a study presented at the annual NUTRITION meeting showed ...

The doctor says there's also early evidence that the same high-fiber diet might improve the success of stem cell transplants, so that's another avenue to watch. Report a correction or typo ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a ...

Nichols described myeloma as a silent but deadly blood cancer with a high mortality rate after diagnosis. She noted that, unlike colon, breast, or prostate cancer, there is no standard screening ...

A precancerous stage known as smoldering myeloma is usually left to watchful waiting. At ASH 2024, a study found a benefit in treating certain patients with Johnson & Johnson drug.

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed ...